Compare Stocks: TVGN, ALXO, BNR, and ORGO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.25 +5.9%	$1.78	$1.05 ▼ $2.66	$172.85M	0.47	1.42 million shs	1.22 million shs
BNR Burning Rock Biotech	$15.49 +1.9%	$12.26	$6.79 ▼ $41.72	$162.92M	1.29	46,343 shs	7,695 shs
ORGO Organogenesis	$1.29 +0.8%	$1.64	$1.25 ▼ $7.08	$165.99M	1.27	668,209 shs	402,066 shs
TVGN Tevogen Bio	$6.78 -4.0%	$7.00	$3.64 ▼ $39.00	$44.15M	0.19	9,768 shs	2,739 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	0.00%	+2.46%	-34.21%	-41.31%	-36.55%
BNR Burning Rock Biotech	0.00%	-4.68%	+33.30%	+37.08%	+74.04%
ORGO Organogenesis	0.00%	-3.01%	-15.69%	-46.25%	-68.77%
TVGN Tevogen Bio	0.00%	-2.87%	-7.00%	+33.99%	-81.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.25 +5.9%	$1.78	$1.05 ▼ $2.66	$172.85M	0.47	1.42 million shs	1.22 million shs
BNR Burning Rock Biotech	$15.49 +1.9%	$12.26	$6.79 ▼ $41.72	$162.92M	1.29	46,343 shs	7,695 shs
ORGO Organogenesis	$1.29 +0.8%	$1.64	$1.25 ▼ $7.08	$165.99M	1.27	668,209 shs	402,066 shs
TVGN Tevogen Bio	$6.78 -4.0%	$7.00	$3.64 ▼ $39.00	$44.15M	0.19	9,768 shs	2,739 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	0.00%	+2.46%	-34.21%	-41.31%	-36.55%
BNR Burning Rock Biotech	0.00%	-4.68%	+33.30%	+37.08%	+74.04%
ORGO Organogenesis	0.00%	-3.01%	-15.69%	-46.25%	-68.77%
TVGN Tevogen Bio	0.00%	-2.87%	-7.00%	+33.99%	-81.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	268.00% Upside
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
ORGO Organogenesis	1.67	Reduce	$4.33	235.92% Upside
TVGN Tevogen Bio	1.50	Reduce	$100.00	1,374.93% Upside

Current Analyst Ratings Breakdown

Latest TVGN, ALXO, BNR, and ORGO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/10/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/4/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	ORGO Organogenesis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$3.00 ➝ $2.00

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
BNR Burning Rock Biotech	$77.16M	2.11	N/A	N/A	$7.28 per share	2.13
ORGO Organogenesis	$564.17M	0.29	$0.65 per share	1.99	$2.36 per share	0.55
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($211.84) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
BNR Burning Rock Biotech	-$7.92M	-$0.87	N/A	N/A	N/A	-13.60%	-12.98%	-8.59%	11/17/2026 (Estimated)
ORGO Organogenesis	$37.03M	-$0.86	N/A	N/A	N/A	-19.94%	-23.89%	-11.13%	11/5/2026 (Estimated)
TVGN Tevogen Bio	-$26.27M	-$4.63	N/A	N/A	N/A	N/A	N/A	-468.32%	11/13/2026 (Estimated)

Latest TVGN, ALXO, BNR, and ORGO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	ALXO ALX Oncology	-$0.15	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	ORGO Organogenesis	-$0.1775	N/A	N/A	N/A	$52.09 million	N/A
9/10/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	-$0.20	+$2.0883	-$0.25	$19.21 million	$19.84 million
8/14/2026	Q2 2026	TVGN Tevogen Bio	-$2.53	-$1.52	+$1.01	-$1.52	N/A	N/A
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/6/2026	Q2 2026	ORGO Organogenesis	-$0.35	-$0.71	-$0.36	-$0.77	$54.27 million	$43.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
BNR Burning Rock Biotech	N/A	3.05	2.90
ORGO Organogenesis	0.07	3.52	3.00
TVGN Tevogen Bio	N/A	0.33	0.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
BNR Burning Rock Biotech	30.03%
ORGO Organogenesis	49.57%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
BNR Burning Rock Biotech	30.30%
ORGO Organogenesis	18.80%
TVGN Tevogen Bio	65.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	48	138.28 million	121.13 million	Optionable
BNR Burning Rock Biotech	667	10.52 million	7.33 million	Not Optionable
ORGO Organogenesis	854	128.68 million	104.48 million	Optionable
TVGN Tevogen Bio	18	6.51 million	2.24 million	N/A

TVGN, ALXO, BNR, and ORGO Headlines

Recent News About These Companies

Tevogen Bio signs non-binding letter of intent with HRK Healthcare

October 8 at 10:43 PM | streetinsider.com

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

September 30, 2026 | globenewswire.com

Tevogen Bio Holdings Rebrands as Tevogen Inc.

July 30, 2026 | tipranks.com

Tevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGN

July 24, 2026 | benzinga.com

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

July 13, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative

June 10, 2026 | finanznachrichten.de

Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions

June 9, 2026 | quiverquant.comQ

Tevogen Announces Formation of a Healthcare Services Initiative

June 9, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | finanznachrichten.de

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...

May 28, 2026 | enidnews.comE

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | globenewswire.com

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...

May 21, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare Transaction

May 21, 2026 | quiverquant.comQ

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 21, 2026 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth Initiatives

May 18, 2026 | quiverquant.comQ

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026 | globenewswire.com

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...

May 12, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLP

May 12, 2026 | quiverquant.comQ

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026 | globenewswire.com

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

May 5, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, ALXO, BNR, and ORGO Company Descriptions

ALX Oncology NASDAQ:ALXO

$1.25 +0.07 (+5.93%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.20 -0.05 (-4.00%)

As of 10/9/2026 07:30 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Burning Rock Biotech NASDAQ:BNR

$15.49 +0.29 (+1.91%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$15.59 +0.10 (+0.65%)

As of 10/9/2026 06:21 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Organogenesis NASDAQ:ORGO

$1.29 +0.01 (+0.78%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.29 0.00 (0.00%)

As of 10/9/2026 04:38 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Tevogen Bio NASDAQ:TVGN

$6.78 -0.28 (-3.97%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$6.96 +0.18 (+2.58%)

As of 10/9/2026 07:58 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TVGN, ALXO, BNR, and ORGO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TVGN, ALXO, BNR, and ORGO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TVGN, ALXO, BNR, and ORGO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, ALXO, BNR, and ORGO Company Descriptions

ALX Oncology NASDAQ:ALXO

Burning Rock Biotech NASDAQ:BNR

Organogenesis NASDAQ:ORGO

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TVGN, ALXO, BNR, and ORGO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TVGN, ALXO, BNR, and ORGO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TVGN, ALXO, BNR, and ORGO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, ALXO, BNR, and ORGO Company Descriptions

ALX Oncology NASDAQ:ALXO

Burning Rock Biotech NASDAQ:BNR

Organogenesis NASDAQ:ORGO

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools